EGFR and non-small cell lung carcinoma: Additionally, a phase I/Ib trial of MRX-2843 is currently recruiting to test MRX-2843 in combination with osimertinib (EGFR inhibitor) in EGFR-mutant NSCLC patients (NCT04762199).